Dose-adjusted dabrafenib combined with trametinib might be a potentially effective treatment strategy for elderly patients with advanced pancreatic adenocarcinoma harboring BRAF V600E mutations, and needs to be further evaluated clinically. This evidence concerns the gene BRAF and pancreatic adenocarcinoma.